Last updated: November 12, 2026
Altoprev was a branded extended-release formulation of lovastatin for hypercholesterolemia. Its commercial position deteriorated because statins became a mature, price-driven category dominated by generic atorvastatin, simvastatin, pravastatin, and immediate-release lovastatin. Public filings do not identify material standalone Altoprev revenue, and the product no longer has a meaningful commercial presence in the U.S. The available record supports a product lifecycle defined by limited differentiation, generic competition, and eventual commercial discontinuation rather than by a major patent or safety event.
What is Altoprev and who marketed it?
Altoprev is the brand name for lovastatin extended-release tablets. Lovastatin is an HMG-CoA reductase inhibitor used to reduce low-density lipoprotein cholesterol and total cholesterol in patients with primary hypercholesterolemia or mixed dyslipidemia.
| Attribute |
Altoprev |
| Active ingredient |
Lovastatin |
| Dosage form |
Extended-release tablet |
| Original indication |
Hypercholesterolemia and mixed dyslipidemia |
| FDA application |
NDA 021366 |
| Initial U.S. approval |
2002 |
| Original developer/marketer |
Andrx Pharmaceuticals |
| Therapeutic class |
Statin |
| Primary competitors |
Lipitor, Zocor, Pravachol, Mevacor, Crestor and later generic statins |
| Current commercial position |
No meaningful branded U.S. market presence |
The product was developed to provide extended-release delivery of lovastatin. Its clinical and commercial value depended on dosing convenience and formulation differentiation rather than on a new active pharmaceutical ingredient. The FDA-approved label described once-daily administration, with dosing generally in the evening because cholesterol synthesis is higher during nighttime hours. [1]
Andrx later became part of Watson Pharmaceuticals, which subsequently became Actavis and then Allergan. The corporate ownership changes complicated brand-level revenue tracking because product sales were generally reported within broader pharmaceutical segments rather than as a separate Altoprev line item. [2, 3]
When did Altoprev lose exclusivity?
Altoprev lost practical market exclusivity during the broader erosion of branded statin pricing. The key commercial loss was not limited to a single patent expiration date. Multiple factors reduced its economic protection:
- Lovastatin was an older molecule with extensive generic availability.
- Competing statins had stronger prescribing positions and larger clinical franchises.
- Immediate-release lovastatin was available at substantially lower prices.
- Generic atorvastatin and simvastatin became standard formulary options.
- The extended-release formulation did not create durable payer or physician differentiation.
The original lovastatin compound had long been off patent before Altoprev launched. The product’s protection therefore depended on formulation-specific intellectual property, regulatory exclusivity, and commercial execution.
The FDA approved Altoprev in 2002, but the record does not support treating 2002 as the start of meaningful molecule-level exclusivity. Altoprev was a formulation product built around an established active ingredient. Any formulation protection would have been narrower than compound protection and vulnerable to design-around strategies.
What patents protected Altoprev?
The Altoprev patent estate was primarily relevant to extended-release lovastatin technology rather than to lovastatin itself. Publicly available regulatory and patent records do not establish a large, durable patent estate that continued to support the product after its commercial decline.
| Patent category |
Relevance to Altoprev |
Commercial effect |
| Lovastatin compound patents |
Generally expired before Altoprev’s commercial maturity |
No lasting protection |
| Extended-release formulation patents |
Potentially relevant to Altoprev dosage form |
Narrow protection and possible design-around exposure |
| Method-of-use patents |
Limited relevance for a mature statin indication |
Weak commercial leverage |
| Manufacturing patents |
Could affect process economics |
No evidence of a major continuing barrier |
| Pediatric exclusivity |
Not a major reported Altoprev value driver |
Limited impact |
| Orphan-drug exclusivity |
Not applicable |
No protection |
The FDA Orange Book is the principal source for patents listed against approved drug products. Historical Orange Book records should be used to distinguish patents listed against Altoprev from patents covering lovastatin generally. A patent associated with a formulation or manufacturing process would not necessarily block all generic lovastatin products. [4]
What is the FDA and Orange Book status of Altoprev?
Altoprev received FDA approval under NDA 021366. The product’s regulatory status should be separated into three issues:
- approval history;
- commercial availability;
- withdrawal for safety or efficacy reasons.
A drug can be discontinued commercially without the FDA determining that its approval should be withdrawn for safety or lack of effectiveness. FDA’s discontinued-drug records are not, by themselves, evidence of a safety recall or regulatory finding against the product. [5]
The available public record does not indicate that Altoprev was removed because of a major safety defect. Its decline is more consistent with commercial discontinuation in a crowded generic statin market.
The current U.S. market does not treat Altoprev as a significant active branded product. Prescribers seeking lovastatin generally encounter generic immediate-release products rather than the Altoprev brand.
Were there Paragraph IV challenges to Altoprev?
There is no strong public evidence of a major, commercially consequential Paragraph IV litigation campaign directed at Altoprev comparable with high-value products such as blockbuster extended-release cardiovascular drugs.
That outcome is commercially rational. A generic company assessing Altoprev would have faced several constraints:
- limited demand for the branded product;
- weak pricing power in the statin class;
- availability of lower-cost lovastatin alternatives;
- potential ability to compete through other dosage forms or formulations;
- limited return on costly patent litigation.
A Paragraph IV certification can challenge listed patents, but it does not guarantee a commercially attractive launch. For Altoprev, the market opportunity was likely too small to justify prolonged patent litigation relative to other cardiovascular products.
What formulations were protected by Altoprev patents?
The commercial distinction was the extended-release formulation. Altoprev was designed to release lovastatin over a longer period than conventional immediate-release lovastatin tablets.
Formulation-related protection can cover:
- release profile;
- matrix or coating technology;
- excipient composition;
- tablet architecture;
- dissolution characteristics;
- manufacturing process;
- dosing regimen linked to the formulation.
The economic value of those claims depends on whether they block clinically substitutable products. A narrow formulation patent may not prevent competition from immediate-release lovastatin, another extended-release design, or a different statin with superior potency and formulary status.
Altoprev’s formulation advantage was therefore vulnerable to therapeutic substitution. Physicians and payers did not need a generic Altoprev-equivalent product to displace the brand. They could use generic simvastatin, atorvastatin, pravastatin, or lovastatin.
How did Altoprev compare with competing statins?
| Product |
Active ingredient |
Historical position |
Competitive pressure on Altoprev |
| Altoprev |
Lovastatin extended-release |
Niche branded formulation |
Direct and indirect pressure |
| Mevacor |
Lovastatin immediate-release |
Original lovastatin brand |
Lower-cost generic substitution |
| Zocor |
Simvastatin |
Major branded statin, later generic |
Strong formulary pressure |
| Lipitor |
Atorvastatin |
Large high-potency franchise |
Strong clinical and commercial pressure |
| Pravachol |
Pravastatin |
Established statin, later generic |
Broad substitution |
| Crestor |
Rosuvastatin |
High-potency branded product |
Clinical differentiation |
| Generic atorvastatin |
Atorvastatin |
High-volume standard therapy |
Severe price pressure |
| Generic simvastatin |
Simvastatin |
Widely available low-cost option |
Severe price pressure |
Altoprev competed in a category where the active ingredient, not the delivery technology, drove most prescribing decisions. Generic atorvastatin became especially damaging because it offered high LDL reduction at low cost. The product’s extended-release design did not create a sufficiently large adherence or tolerability advantage to offset this pressure.
What was Altoprev’s financial trajectory?
Altoprev’s financial trajectory can be characterized in four phases.
Launch and early commercialization
The product entered a mature cardiovascular market in 2002. Its launch depended on differentiation from conventional lovastatin, but the statin category already had established brands, clinical familiarity, and payer controls.
Limited niche positioning
Altoprev could support a niche prescription base among patients for whom an extended-release formulation was considered useful. The product did not become a major revenue contributor relative to large statin brands.
Accelerated erosion
As generic statins became preferred formulary products, Altoprev faced declining prescription volume and weaker reimbursement. Pharmacy benefit managers could substitute generic statins without relying on a generic product that exactly replicated Altoprev’s formulation.
Commercial discontinuation
The product’s economics likely became unfavorable because manufacturing, distribution, regulatory maintenance, and sales costs could not be supported by remaining demand. Public company filings do not provide a reliable standalone Altoprev revenue series, so precise annual sales, peak revenue, and cumulative revenue cannot be stated from the public record.
The absence of standalone revenue disclosure is itself informative. Products with material financial exposure are commonly identified in company filings, investor presentations, or product-level disclosures. Altoprev did not maintain that level of reporting prominence in the publicly available filings of its successive corporate owners. [2, 3]
What revenue exposure did Altoprev create for its owners?
Altoprev did not represent a material concentration risk for the large pharmaceutical companies that owned or marketed it. The product was one asset within broader portfolios containing generic, specialty, branded, and over-the-counter medicines.
Its financial exposure was more relevant at the product-maintenance level:
- declining net sales;
- lower reimbursement;
- limited ability to raise price;
- manufacturing complexity relative to immediate-release lovastatin;
- declining promotional return;
- potential inventory and supply-chain costs.
The product’s discontinuation would have had little effect on the overall financial trajectory of a diversified owner. It could, however, reduce revenue modestly while eliminating the costs of maintaining a low-volume product.
What manufacturing and intellectual-property barriers remain?
Altoprev’s manufacturing barriers were likely moderate rather than prohibitive. Extended-release tablets require control of dissolution, content uniformity, stability, and batch reproducibility. These requirements can complicate generic development, but they do not create the same barriers as sterile injectables, complex biologics, inhaled products, or drug-device combinations.
The principal barriers were:
- formulation development;
- bioequivalence testing;
- dissolution matching;
- manufacturing scale-up;
- FDA approval requirements;
- limited commercial return.
The active ingredient, lovastatin, is chemically established and available through generic supply channels. There is no indication that proprietary manufacturing know-how created a continuing market barrier sufficient to preserve Altoprev’s branded value.
Which companies challenged or displaced Altoprev?
No single challenger appears to have captured the Altoprev market through a headline litigation victory. Displacement occurred through the broader generic and therapeutic-substitution system.
The most important competitive forces were:
- generic lovastatin manufacturers;
- generic simvastatin manufacturers;
- generic atorvastatin manufacturers;
- generic pravastatin manufacturers;
- branded and generic rosuvastatin products;
- pharmacy benefit manager formulary substitution.
This distinction matters. Altoprev’s commercial decline did not require a direct generic copy to enter immediately after a successful Paragraph IV challenge. Payers could replace it with other statins that delivered the same broad treatment objective at lower cost.
What generic launch scenarios existed for Altoprev?
Three launch scenarios were commercially plausible:
| Scenario |
Description |
Commercial outcome |
| Direct generic |
Generic extended-release lovastatin enters after resolving listed-patent issues |
Limited market due to weak demand |
| Formulation workaround |
Competitor develops a different release technology |
Possible regulatory entry, uncertain uptake |
| Therapeutic substitution |
Payers shift patients to generic atorvastatin, simvastatin or pravastatin |
Most commercially important scenario |
The third scenario was the dominant risk. A direct Altoprev-equivalent launch would have validated the product’s formulation but would not have been necessary to destroy its branded pricing.
What litigation and settlement agreements affected Altoprev?
There is no widely reported major patent settlement associated with Altoprev that materially preserved its commercial franchise. The public record does not identify a settlement comparable with high-value pharmaceutical cases involving delayed generic entry, large payments, or broad launch restrictions.
The absence of major settlement activity is consistent with the product’s limited market value. Patent disputes generally become economically significant when a product has substantial remaining sales and a generic challenger can capture a large market. Altoprev’s mature category and substitutable alternatives reduced that incentive.
How strong was the Altoprev patent estate?
The Altoprev estate was commercially weak to moderate and narrower than the estates of products protected by compound patents, multiple formulation patents, method-of-use claims, and manufacturing claims.
| Strength factor |
Assessment |
| Novel active ingredient |
Weak |
| Compound patent duration |
Exhausted or commercially irrelevant |
| Formulation differentiation |
Moderate but narrow |
| Method-of-use protection |
Limited |
| Generic substitution risk |
High |
| Direct litigation value |
Low |
| Manufacturing complexity |
Moderate |
| Long-term pricing power |
Low |
| Biosimilar exposure |
None |
Altoprev was a small-molecule product, so biosimilar risk does not apply. The relevant competitors were generic drugs approved under the ANDA pathway, not biosimilars approved under the BPCIA pathway.
Key Takeaways
- Altoprev was an extended-release lovastatin product approved by the FDA in 2002 under NDA 021366.
- Its market position depended on formulation differentiation, not a new active ingredient.
- Generic statins and therapeutic substitution were more important threats than a direct Altoprev generic.
- The product did not develop into a major branded cardiovascular franchise.
- Public filings do not provide dependable standalone Altoprev revenue figures.
- The available record does not show a major safety-driven withdrawal or commercially significant Paragraph IV litigation.
- The product’s patent position was narrower and less durable than estates built around novel molecules.
- Altoprev’s commercial decline reflects mature-market price erosion, formulary substitution, and limited formulation value.
FAQs About Altoprev Market and Patent Status
Is Altoprev still available in the United States?
Altoprev no longer has a meaningful active branded U.S. market presence. Generic lovastatin and other statins remain the relevant treatment alternatives.
Is Altoprev the same as lovastatin?
Altoprev contains lovastatin but uses an extended-release formulation. Generic lovastatin products are generally immediate-release tablets and are not automatically identical to Altoprev’s dosage form.
Did Altoprev have FDA exclusivity?
Altoprev received FDA approval, but its commercial protection did not resemble the exclusivity associated with a new molecular entity. Its value depended mainly on formulation-related protection and brand marketing.
Are there biosimilars to Altoprev?
No. Altoprev is a small-molecule drug. Its competitive products are generics, not biosimilars.
Why did Altoprev lose market share?
The product faced generic statins, formulary substitution, limited clinical differentiation, and weak pricing power. A direct generic version was not required for payers and physicians to move patients away from the brand.
References
-
U.S. Food and Drug Administration. (2002). Altoprev (lovastatin extended-release tablets) prescribing information, NDA 021366.
-
Watson Pharmaceuticals, Inc. (2007). Annual report on Form 10-K for the fiscal year ended December 31, 2006. U.S. Securities and Exchange Commission.
-
Actavis, Inc. (2014). Annual report on Form 10-K for the fiscal year ended December 31, 2013. U.S. Securities and Exchange Commission.
-
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
-
U.S. Food and Drug Administration. (n.d.). Discontinued drug product list and FDA drug approval databases.
